FBIO
Price
$1.89
Change
-$0.10 (-5.03%)
Updated
Jul 11 closing price
Capitalization
55.89M
PGEN
Price
$1.83
Change
-$0.08 (-4.19%)
Updated
Jul 11 closing price
Capitalization
540.18M
30 days until earnings call
Interact to see
Advertisement

FBIO vs PGEN

Header iconFBIO vs PGEN Comparison
Open Charts FBIO vs PGENBanner chart's image
Fortress Biotech
Price$1.89
Change-$0.10 (-5.03%)
Volume$438.27K
Capitalization55.89M
Precigen
Price$1.83
Change-$0.08 (-4.19%)
Volume$1.35M
Capitalization540.18M
FBIO vs PGEN Comparison Chart in %
Loading...
FBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FBIO vs. PGEN commentary
Jul 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FBIO is a Hold and PGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 13, 2025
Stock price -- (FBIO: $1.89 vs. PGEN: $1.83)
Brand notoriety: FBIO and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FBIO: 229% vs. PGEN: 68%
Market capitalization -- FBIO: $55.89M vs. PGEN: $540.18M
FBIO [@Biotechnology] is valued at $55.89M. PGEN’s [@Biotechnology] market capitalization is $540.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FBIO’s FA Score shows that 1 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • FBIO’s FA Score: 1 green, 4 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, FBIO is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FBIO’s TA Score shows that 6 TA indicator(s) are bullish while PGEN’s TA Score has 6 bullish TA indicator(s).

  • FBIO’s TA Score: 6 bullish, 4 bearish.
  • PGEN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both FBIO and PGEN are a good buy in the short-term.

Price Growth

FBIO (@Biotechnology) experienced а +0.53% price change this week, while PGEN (@Biotechnology) price change was +12.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.14%. For the same industry, the average monthly price growth was +16.46%, and the average quarterly price growth was +20.75%.

Reported Earning Dates

FBIO is expected to report earnings on May 15, 2025.

PGEN is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+9.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PGEN($540M) has a higher market cap than FBIO($55.9M). PGEN YTD gains are higher at: 63.393 vs. FBIO (-6.667). FBIO has higher annual earnings (EBITDA): -89.64M vs. PGEN (-154.85M). FBIO has more cash in the bank: 91.3M vs. PGEN (80.2M). PGEN has less debt than FBIO: PGEN (5.42M) vs FBIO (74.2M). FBIO has higher revenues than PGEN: FBIO (57.8M) vs PGEN (4.2M).
FBIOPGENFBIO / PGEN
Capitalization55.9M540M10%
EBITDA-89.64M-154.85M58%
Gain YTD-6.66763.393-11%
P/E RatioN/AN/A-
Revenue57.8M4.2M1,376%
Total Cash91.3M80.2M114%
Total Debt74.2M5.42M1,370%
FUNDAMENTALS RATINGS
FBIO vs PGEN: Fundamental Ratings
FBIO
PGEN
OUTLOOK RATING
1..100
726
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5038
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FBIO's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for PGEN (70) in the null industry. This means that FBIO’s stock grew somewhat faster than PGEN’s over the last 12 months.

FBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that FBIO’s stock grew similarly to PGEN’s over the last 12 months.

FBIO's SMR Rating (100) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that FBIO’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (38) in the null industry is in the same range as FBIO (50) in the Biotechnology industry. This means that PGEN’s stock grew similarly to FBIO’s over the last 12 months.

PGEN's P/E Growth Rating (100) in the null industry is in the same range as FBIO (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to FBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FBIOPGEN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 20 days ago
84%
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
FBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KAUAX6.05N/A
N/A
Federated Hermes Kaufmann A
GSPCX14.37N/A
N/A
Goldman Sachs Large Cap Equity C
MRSPX15.79N/A
N/A
BlackRock Advantage SMID Cap R
GGHPX8.01N/A
N/A
Goldman Sachs Intl Eq Div & Prem P
VIDMX10.27N/A
N/A
Virtus KAR Developing Markets I

FBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, FBIO has been loosely correlated with CRBP. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if FBIO jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FBIO
1D Price
Change %
FBIO100%
-5.03%
CRBP - FBIO
38%
Loosely correlated
-1.08%
AXON - FBIO
38%
Loosely correlated
-0.46%
ABOS - FBIO
36%
Loosely correlated
+7.69%
KYTX - FBIO
35%
Loosely correlated
+12.89%
QSI - FBIO
34%
Loosely correlated
-4.42%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-4.19%
CRSP - PGEN
48%
Loosely correlated
-3.73%
ARCT - PGEN
48%
Loosely correlated
-4.83%
ALEC - PGEN
46%
Loosely correlated
-6.40%
BEAM - PGEN
46%
Loosely correlated
-3.95%
XENE - PGEN
46%
Loosely correlated
-2.33%
More